Investorideas.com

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Immunotherapeutic Agent Shows Efficacy in Rare Respiratory Disease
April 11, 2019 (Investorideas.com Newswire) Trial results for this therapeutic, and their implications for this biotech, were discussed in an H.C. Wainwright & Co. report.

Frost & Sullivan Reveals Five Patient Monitoring Solutions to Accelerate Universal Health Coverage
Santa Clara, Calif. - April 8, 2019 (Investorideas.com Newswire) Today is World Health Day, and this year's theme is "Universal Health Coverage: Everyone, Everywhere-#HealthforAll."

Biopharma's Early Data Show Immunotherapy's Efficacy in Ovarian Cancer
April 1, 2019 (Investorideas.com Newswire) The "encouraging" data for this drug candidate as a monotherapy is the focus of an H.C. Wainwright & Co. report.

San Diego Biopharma Features 'Strong and Balanced Pipeline'
March 28, 2019 (Investorideas.com Newswire) An H.C. Wainwright & Co. report discussed what sets this company's asset apart from similar products.

Here Comes the "Antibody Boom"; (TSXV: $IPA.V) (OTC: $IPATF) (TSX: $ZYME.TO) (NASDAQ: $SESN) (TSX: $PMN.TO)
Point Roberts, WA and Delta, BC - March 28, 2019 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market dominance.

Positive Results and New Technology Give Rise to Antibody Dominance; (TSXV: $IPA.V) (OTC: $IPATF) (TSX: $ZYME.TO) (NASDAQ: $SESN) (TSX: $PMN.TO)
Point Roberts, WA and Delta, BC - March 27, 2019 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market dominance.

Medical Tech News: CardioComm Solutions (TSXV: EKG) Launches New GEM(TM) Mobile Universal ECG App Expanding ECG Reporting Services Across Global Markets
Toronto, Ontario - March 25, 2019 (Newsfile Corp.) (Investorideas.com Newswire) CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, announces the release of a new version of the Company's recently cleared US Food and Drug Administration ("FDA") GEMS Mobile ECG app.

Rare Diseases Biotech Provides Opportunity
March 22, 2019 (Investorideas.com Newswire) A ROTH Capital Partners report discussed why the stock price is at its current level and noted upcoming catalysts for the company.

Investor Ideas Adds Recent Nasdaq IPO Stocks: Biotech, China-Asia and Energy Sectors - ( $KLDO), ( $INMB), ( $SXTC), ( $MDJH) ( $MTC), ( $NFE)
Point Roberts, WA and Delta, BC - March 22, 2019 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week's additions to its global stock directories in biotech, China-Asia and energy.

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'
March 21, 2019 (Investorideas.com Newswire) The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Biotech News from Newsfile

PreveCeutical Partnership Leads to Two New Patent Filings
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that the Company's research collaboration with UniQuest and The University of Queensland ("UQ") has led to the filing of two new patent applications for cyclic peptides and their use in pain management (the "Patent Applications").The Patent Applications follow from PreveCeutical entering into a research agreement in 2018 (see news release dated ...

PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the Company's research team at the University of Queensland has filed an application to a local hospital's Human Ethics Committee (the "Human Ethics Committee") to acquire human nasal mucosal tissue (mucosal membrane) for use in the final phase of the cannabinoid-based, soluble gel ("Sol-gel") drug delivery research and development program (the ...

Genprex Featured in NetworkNewsAudio Broadcast on Potential Gene Therapy Treatment for Cancer
New York, New York--(Newsfile Corp. - April 12, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio broadcast titled, "Potential Blockbuster Gene Therapy Programs to Watch in 2019."To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/j1WMsTo read the full editorial, visit: http://nnw.fm/YC9iqGenprex already has over 30 issued patents for its platform technologies. The company's promising pipeline currently includes a phase I/II clinical trial underway to evaluate intravenous Oncoprex immunogene therapy in combination ...

Genprex (GNPX) Featured in NetworkNewsWire Publication about Revolutionary Gene Therapies
New York, New York--(Newsfile Corp. - April 11, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled "Potential Blockbuster Gene Therapy Programs to Watch in 2019," visit: http://nnw.fm/YC9iqPerhaps no other disease strikes as much dread and fear as cancer. Many successful treatments are available today that didn't exist just a ...

In a Major Breakthrough, Q BioMed Discovers First Biomarkers for Pediatric Nonverbal Autism Subgroup
Marks the first time a company has identified biomarkers that hold the potential to stratify this subset of patientsStudy examined 1,953 significant autistic biomarkers, resulting in 2 significant markers tied to expressed genes and pathways responsible for speech developmentBiomarkers in the nonverbal subset were distinct from children with typical speech development with or without autismBiomarkers will help homogenize clinical trial participants and will be studied as possible diagnostic and prognostic indicators during trialsNew York, New ...

Subscribe to Biotech News

Biotech News from GlobeNewswire

Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Meetings
Posters to be presented on gene therapy and visual acuity

Posters to be presented on gene therapy and visual acuity

Mateon Enters into Merger Agreement with Oncotelic
Forms Late Clinical-Stage Cancer Immunotherapy Company Focusing on TGF-β RNA Therapeutics

Forms Late Clinical-Stage Cancer Immunotherapy Company Focusing on TGF-β RNA Therapeutics

Genfit: GENFIT Announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC

GENFIT Announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC

Genfit : GENFIT annonce l’attribution de la Breakthrough Therapy Designation à elafibranor, par la FDA, pour le traitement de la PBC

GENFIT annonce l’attribution de la Breakthrough Therapy Designation à elafibranor, par la FDA, pour le traitement de la PBC

HOOKIPA Pharma Announces Pricing of Initial Public Offering

NEW YORK, April 17, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $14.00 per share. In addition, HOOKIPA has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $84 million, excluding any exercise of the underwriters’ option to purchase additional shares.

Subscribe to Biotech News

Biotech/ Pharma Stock Directory

Preview

4SC (XETRA: VSC.DE) is an innovative biotech company with a strong focus on clinical development. We discover and develop targeted small molecule drugs with an epigenetic mode of action for the treatment of cancer in indications with a high unmet medical need and major economic potential.

Aastrom Biosciences, Inc. (NasdaqCM: ASTM) is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI(TM), a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

ABBOTT LABORATORIES (NYSE: ABT) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.76

Abeona Therapeutics Inc. (NasdaqCM:ABEO) develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process.

Ablynx (Brussels: ABLX.BR) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease.

Acadia Pharmaceuticals Inc. (NasdaqGS: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, for which we have reported positive Phase III trial results in Parkinson's disease psychosis and which has the potential to be the first drug approved in the United States for this disorder. We are currently completing NDA-enabling clinical and manufacturing activities for pimavanserin and are planning to submit an NDA with the FDA near the end of 2014. Pimavanserin is also in Phase II development for Alzheimer's disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two preclinical programs directed at Parkinson's disease and other neurological disorders. All product candidates are small molecules that emanate from internal discoveries.

Access Pharmaceuticals, Inc. (OTC:ACCP) is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access developed MuGard and ProctiGard and is developing multiple follow-on products. Access also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.

AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company's late-stage pipeline includes ARX-04 (sufentanil sublingual tablet, 30 mcg), designed for the treatment of moderate-to-severe acute pain in medically supervised settings; and Zalviso® (sufentanil sublingual tablet system), designed for the management of moderate-to-severe acute pain in adult patients in the hospital setting. Zalviso delivers 15 mcg sufentanil sublingually through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. Zalviso is approved in the EU as well as Norway, Iceland, and Liechtenstein and is investigational and in late-stage development in the U.S. Grunenthal Group holds the rights for Zalviso in Europe and Australia, while AcelRx retains all other world-wide rights.

Acorda Therapeutics, Inc. (NasdaqGS:ACOR) is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders. Acorda markets three FDA-approved therapies including: AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure.

Acrux Limited (ASX:ACR.AX) is a dynamic Australian drug delivery business developing and commercialising a range of patient-preferred pharmaceutical products for global markets, using innovative, patented technology to administer drugs through the skin. Fast drying, non-occlusive topical sprays or liquids provide an enhanced transdermal delivery platform with low or no skin irritation, superior cosmetic acceptability, and simple, accurate and flexible dosing.

See the full stock directory here

Sponsored Content

5 Key Tips For Renting a Boardroom

August 14, 2018 (Investorideas.com Newswire) You've arranged to rent virtual offices in Toronto from time to time.

How to Go About Choosing a Medical Malpractice Lawyer

February 13, 2018 (Investorideas.com Newswire) Medical malpractice affects thousands of individuals around the world. If you think you have been injured, or wrongfully treated by a medical professional, you may be entitled to compensation.